Allergan (AGN)
193.02
0.00 (0.00%)
Upcoming Events
Latest Headlines
Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
October 14, 2022 7:00 AM - Globe NewsWire
Form 6-K AEGON NV For: Oct 14
October 14, 2022 6:41 AM - SEC Filing
Aegon completes sale of 50% stake in joint venture with Liberbank to Unicaja Banco
October 14, 2022 4:30 AM - Globe NewsWire
Form 6-K AEGON NV For: Sep 28
September 28, 2022 6:08 AM - SEC Filing
Form 6-K AEGON NV For: Sep 28
September 28, 2022 6:07 AM - SEC Filing
Aegon to repurchase shares to neutralize 2022 interim dividend paid in shares
September 27, 2022 3:35 PM - Globe NewsWire
Aegon completes share buyback program to neutralize 2021 final dividend paid in shares
September 27, 2022 3:30 PM - Globe NewsWire
Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program
September 21, 2022 7:00 AM - Globe NewsWire
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
September 19, 2022 7:00 AM - Globe NewsWire
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
September 12, 2022 7:00 AM - Globe NewsWire
Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami
September 8, 2022 7:00 AM - Globe NewsWire
Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
September 1, 2022 7:00 AM - Globe NewsWire
Form 6-K/A AEGON NV For: Jun 30
August 31, 2022 12:15 PM - SEC Filing
Aegon Bank publishes its first half 2022 report
August 29, 2022 2:00 AM - Globe NewsWire
Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
August 23, 2022 7:15 AM - Globe NewsWire
Form 6-K AEGON NV For: Jun 30
August 11, 2022 10:27 AM - SEC Filing
Form 6-K AEGON NV For: Aug 11
August 11, 2022 10:23 AM - SEC Filing
Form 6-K AEGON NV For: Aug 11
August 11, 2022 10:20 AM - SEC Filing
Aegon reports second quarter 2022 results
August 11, 2022 1:30 AM - Globe NewsWire
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
August 3, 2022 7:07 AM - Globe NewsWire
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
July 28, 2022 7:00 AM - Globe NewsWire
Full Article List